(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.34% ¥ 2 300.00
Live Chart Being Loaded With Signals
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors...
Stats | |
---|---|
Tagesvolumen | 3.19M |
Durchschnittsvolumen | 2.18M |
Marktkapitalisierung | 1 048.85B |
EPS | ¥0 ( 2024-01-30 ) |
Nächstes Ertragsdatum | ( ¥51.38 ) 2024-05-08 |
Last Dividend | ¥37.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 8.71 |
ATR14 | ¥1.094 (0.05%) |
Volumen Korrelation
Ono Pharmaceutical Co., Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Ono Pharmaceutical Co., Korrelation - Währung/Rohstoff
Ono Pharmaceutical Co., Finanzdaten
Annual | 2022 |
Umsatz: | ¥447.19B |
Bruttogewinn: | ¥337.13B (75.39 %) |
EPS: | ¥230.85 |
FY | 2022 |
Umsatz: | ¥447.19B |
Bruttogewinn: | ¥337.13B (75.39 %) |
EPS: | ¥230.85 |
FY | 2022 |
Umsatz: | ¥361.36B |
Bruttogewinn: | ¥267.85B (74.12 %) |
EPS: | ¥162.19 |
FY | 2021 |
Umsatz: | ¥309.28B |
Bruttogewinn: | ¥223.71B (72.33 %) |
EPS: | ¥151.11 |
Financial Reports:
No articles found.
Ono Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥33.00 (N/A) |
¥0 (N/A) |
¥37.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥6.80 | 2001-03-27 |
Last Dividend | ¥37.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 41 | -- |
Total Paid Out | ¥671.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.41 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.48 | |
Div. Directional Score | 10.00 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7987.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7222.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6462.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5482.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
4471.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3657.T | Ex Dividend Junior | 2024-01-30 | Annually | 0 | 0.00% | |
2910.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
1721.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9766.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8850.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.256 | 1.500 | 4.88 | 7.31 | [0 - 0.5] |
returnOnAssetsTTM | 0.143 | 1.200 | 5.23 | 6.28 | [0 - 0.3] |
returnOnEquityTTM | 0.166 | 1.500 | 9.26 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.291 | -1.000 | 7.09 | -7.09 | [0 - 1] |
currentRatioTTM | 3.95 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.140 | 1.500 | 4.78 | 7.17 | [0.2 - 2] |
debtRatioTTM | 0.00963 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 99.03 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 222.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 191.88 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0109 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.756 | 1.000 | 0.740 | 0.740 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.329 | 1.000 | 5.41 | 5.41 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 12.35 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.559 | 0.800 | 9.61 | 7.69 | [0.5 - 2] |
Total Score | 12.67 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.53 | 1.000 | 9.24 | 0 | [1 - 100] |
returnOnEquityTTM | 0.166 | 2.50 | 9.53 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 191.88 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.50 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 222.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.291 | 1.500 | 7.09 | -7.09 | [0 - 1] |
pegRatioTTM | 1.164 | 1.500 | 5.58 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.213 | 1.000 | 7.18 | 0 | [0.1 - 0.5] |
Total Score | 7.48 |
Ono Pharmaceutical Co.,
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.